主页 > 医学前沿 >
【medical-news】前景光明：Novavax公司禽流感疫苗取
诺华离禽流感疫苗的申请越来越近
By Kendra Marr
Washington Post Staff Writer
Wednesday, August 27, 2008; Page D04
肯德拉.马尔
华盛顿专职作家
星期三，2008年8月27日，D04页
Novavax said yesterday that its bird flu vaccine elicited a robust immune response in humans, moving the biotech a step closer to licensing its pandemic vaccine production system.
昨天诺华公司宣布，禽流感疫苗可以在人体内引起强大的免疫应答，离流感疫苗生产的申请系统越来越近了。
In the trial, 160 patients received two vaccine injections, of 15 to 90 micrograms, one month apart. Of the patients who received the highest dosage, 94 percent produced antibodies to neutralize H5N1, an Indonesian strain of bird flu that emerged in 2005 and has been linked to 110 deaths.
实验中，160名患者在一个月的间隔期中分别接受两次疫苗的接种，从15微克到90微克不等。接种高剂量疫苗的的患者，94%可以产生抗体来中和体内的H5N1病毒，此禽流感病毒株品种2005年出现在印度尼西亚并造成110人丧生。
"These results are strong and very competitive," said Rahul Singhvi, Novavax's chief executive.
诺华的首席执行官胡尔.幸格维称这些结果非常强烈和十分具有竞争力。
Shares of Novavax fell 6 cents, or 2 percent, to $2.91.
诺华的股票下跌了2%，下跌6美分至2.91美元。
Novavax has had a demo of the vaccine manufacturing process set up at its Rockville headquarters since May 1 but does not have a buyer.
诺华自从五月一号后就在洛克威尔总部拥有了疫苗制造程序的样本，尽管目前还没有一个买家。
There were 385 cases of bird flu in humans, leading to 243 deaths, from 2003 to June 19, according to the World Health Organization's most recent data. Outbreaks have mostly centered on Asia.
根据世界卫生组织的最新数据显示，自从2003年至2008年6月19日，已经出现了385例禽流感病人，造成了243人死亡，禽流感的爆发基本集中在亚洲。
Many large multinational biotechs -- GlaxoSmithKline, Sanofi-Aventis, Novartis -- are working on bird flu vaccines in the United States and Western Europe under government contract, said Ken Trbovich, an analyst with RBC Capital Markets.
RBC资产公司的分析员肯.托博韦切称，很多大型跨国生物技术公司，如葛兰素史克，赛诺菲-万奈特，诺华在美国和欧洲都与政府签订了协议进行禽流感病毒疫苗的开发。
Novavax has partnered with GE Healthcare to reach the rest of the world by providing other countries a system to quickly mass-produce vaccines.
诺华与通用保健合作向世界其他国家提供快速生产疫苗的系统。
"If you truly believe a pandemic outbreak is likely, there is reason to believe foreign governments and the U.S. will clamp down and control the supply," Trbovich said. He added, "Other places in the world may have a lot of money, but no amount of money will get you vaccines in the case of a pandemic."
托博韦切称，如果你确信有可能爆发流感，那么就有理由相信外国政府和美国将会取缔和控制疫苗的供应。他并补充说到，世界上有些地方钱可能不是问题，但是一旦流感暴发的话，你可能就没钱买疫苗了。
Traditionally, to create flu vaccines, drugmakers grow live virus strains in chicken eggs, which act as incubators. The virus is later killed and bottled into a vaccine. But eggs are a volatile medium, and a scarce supply essentially stops production.
传统意义上来说，培养流感疫苗是制药者以鸡胚为培养箱，将病毒株放入鸡胚中生长。病毒然后就死亡了并生成疫苗。但是，鸡胚往往不是很稳定，并且产量少阻止了大规模生产。
Novavax's bird flu vaccine uses particles that mimic the size and shape of the virus, which trigger an immune response but lack the genetic material to replicate.
诺华发明的禽流感疫苗利用了模拟病毒大小和形状的颗粒，这足以激发免疫应答但并不含有病毒复制需要的遗传物质。
Because the particles are produced in more stable insect-cell cultures, yields are seven to 10 times higher than egg-based manufacturing, Novavax said. The vaccine can also be created within 10 to 12 weeks of identifying a pandemic strain -- half the time it takes to make egg-based vaccines.
瓦克斯说，由于病毒颗粒是由更稳定的昆虫细胞培养出来，产量要高出鸡胚培养系统7-10倍。一个流行病毒株的疫苗也可以通过该系统产生，大约需要10-12周，花费的时间是利用鸡胚系统培养所需时间的一半。
GE is developing the production equipment, which is cheap to set up and run in case of a pandemic.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-05 17:14
医学,生命科学网